ZYVERSA THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Basic
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Net Income (Loss) Available to Common Stockholders, Basic of -$9.41 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2025-03-27
- ZYVERSA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-12-31 was -$1.42M.
- ZYVERSA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-09-30 was -$2.40M.
- ZYVERSA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-06-30 was -$2.76M.
- ZYVERSA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-03-31 was -$2.83M.
- ZYVERSA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was -$9.41M.
- ZYVERSA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$106.25M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 1 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 11 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|---|
| 2024-12-31 | -$1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$3.82M derived: sum of 2 quarters · filed 2025-03-27 | -$6.59M derived: sum of 3 quarters · filed 2025-03-27 | -$9.41M 10-K · filed 2025-03-27 | ||
| 2024-09-30 | -$2.40M 10-Q · filed 2024-11-14 | -$5.16M derived: sum of 2 quarters · filed 2024-11-14 | -$7.99M 10-Q · filed 2024-11-14 | -$21.33M derived: sum of 4 quarters · filed 2025-03-27 | ||
| 2024-06-30 | -$2.76M 10-Q · filed 2024-08-09 | -$5.59M 10-Q · filed 2024-08-09 | -$18.93M derived: sum of 3 quarters · filed 2025-03-27 | -$21.86M derived: sum of 4 quarters · filed 2025-03-27 | ||
| 2024-03-31 | -$2.83M derived: 10-K 12 month − 3 quarters · filed 2025-03-27 | -$16.17M derived: sum of 2 quarters · filed 2025-03-27 | -$19.10M derived: sum of 3 quarters · filed 2025-03-27 | -$105.53M derived: sum of 4 quarters · filed 2025-03-27 | ||
| 2023-12-31 | -$13.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$16.27M derived: sum of 2 quarters · filed 2025-03-27 | -$102.70M derived: sum of 3 quarters · filed 2025-03-27 | -$106.25M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | -$2.93M 10-Q · filed 2024-11-14 | -$89.36M derived: sum of 2 quarters · filed 2024-11-14 | -$92.91M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$86.43M 10-Q · filed 2024-08-09 | -$89.97M 10-Q · filed 2024-08-09 | ||||
| 2022-12-31 | -$75.02K 10-K · filed 2024-03-25 | |||||
| 2022-12-12 | -$24.06M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |